Maze Therapeutics adds Paula Johnson and Sophie Kornowski to board
The two appointments, effective August 13, 2026, rebalance board classes as Maze advances its kidney and metabolic disease pipeline toward late-stage development.
SEC filing
Latest
3 stories
Monday, August 17
Tuesday, August 11
Maze Therapeutics reports Q2 2026 results, cites progress on kidney disease pipeline
Maze says enrollment continues in its Phase 2 HORIZON and CIPheR trials, with cash runway extended into 2029.
SEC filing